MAIA Biotechnology Files 8-K on Director/Officer Changes
Ticker: MAIA · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1878313
Sentiment: neutral
Topics: management-change, corporate-governance, filing
TL;DR
MAIA Bio shakes up board and execs, files 8-K.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on February 6, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported being February 1, 2025. The company is incorporated in Delaware and headquartered in Chicago, IL.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive leadership can introduce uncertainty about the company's future direction and stability.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- February 1, 2025 (date) — Earliest event reported
- February 6, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Chicago, IL (location) — Principal executive offices
FAQ
What specific changes were made regarding directors and officers?
The filing indicates the departure of directors, election of new directors, and appointment of certain officers, along with details on compensatory arrangements for these officers.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is February 1, 2025.
Where is MAIA Biotechnology, Inc. headquartered?
MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What other items are included in this filing besides director and officer changes?
The filing also includes Financial Statements and Exhibits.
Filing Stats: 1,684 words · 7 min read · ~6 pages · Grade level 15.1 · Accepted 2025-02-06 16:30:52
Key Financial Figures
- $625,000 — is entitled to an annual base salary of $625,000, an increase from $473,000 under his pr
- $473,000 — se salary of $625,000, an increase from $473,000 under his prior employment agreement. D
- $489,000 — is entitled to an annual base salary of $489,000, an increase from $363,000 under his pr
- $363,000 — se salary of $489,000, an increase from $363,000 under his prior employment agreement. D
- $275,000 — dated August 30, 2023 was increased to $275,000 per annum from $250,000 per annum. It
- $250,000 — as increased to $275,000 per annum from $250,000 per annum. Item 9.01 Financial Statem
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex10-1.htm (EX-10.1) — 225KB
- ex10-2.htm (EX-10.2) — 233KB
- 0001493152-25-005205.txt ( ) — 786KB
- maia-20250201.xsd (EX-101.SCH) — 3KB
- maia-20250201_lab.xml (EX-101.LAB) — 33KB
- maia-20250201_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 6, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name : Vlad Vitoc Title: Chief Executive Officer 4